table of contents table of contents

The authors describe a novel lentiviral packaging system in which not only …

Home » Biology Articles » Virology » Design of a trans protease lentiviral packaging system that produces high titer virus » References

- Design of a trans protease lentiviral packaging system that produces high titer virus

  1. Frankel AD, Young JA: HIV-1: fifteen proteins and an RNA.

    Annu Rev Biochem 1998, 67:1-25.


  2. Luciw PA: Human Immunodeficiency Viruses and Their Replication, In B.N. Fields, D.M. Knipe, P.M. Howely, R.M. Chanock, J.L. Melnick, T.P. Monath, B. Roizman, and S.E. Straus (ed), Field Virology . 3rd edition. Philadelphia, Pa , Lippincott-Raven Publishers; 1996:1881-1975.


  3. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE: Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

    Nature 1988, 331(6153):280-283.


  4. Dulude D, Berchiche YA, Gendron K, Brakier-Gingras L, Heveker N: Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1.

    Virology 2006, 345(1):127-136.


  5. Luukkonen BG, Fenyo EM, Schwartz S: Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.

    Virology 1995, 206(2):854-865.


  6. Shehu-Xhilaga M, Crowe SM, Mak J: Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

    J Virol 2001, 75(4):1834-1841.


  7. Wills JW, Craven RC, Weldon RA Jr., Nelle TD, Erdie CR: Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

    J Virol 1991, 65(7):3804-3812.


  8. Park J, Morrow CD: Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.

    J Virol 1991, 65(9):5111-5117.


  9. Rose JR, Babe LM, Craik CS: Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.

    J Virol 1995, 69(5):2751-2758.


  10. Shehu-Xhilaga M, Kraeusslich HG, Pettit S, Swanstrom R, Lee JY, Marshall JA, Crowe SM, Mak J: Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation.

    J Virol 2001, 75(19):9156-9164.


  11. Vogt VM: Proteolytic processing and particle maturation.

    Curr Top Microbiol Immunol 1996, 214:95-131.


  12. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG: Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

    J Virol 1998, 72(4):2846-2854.


  13. Katoh I, Ikawa Y, Yoshinaka Y: Retrovirus protease characterized as a dimeric aspartic proteinase.

    J Virol 1989, 63(5):2226-2232.


  14. Krausslich HG: Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.

    Proc Natl Acad Sci U S A 1991, 88(8):3213-3217.


  15. Pearl LH, Taylor WR: A structural model for the retroviral proteases.

    Nature 1987, 329(6137):351-354.


  16. Pettit SC, Gulnik S, Everitt L, Kaplan AH: The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

    J Virol 2003, 77(1):366-374.


  17. Wu X, Liu H, Xiao H, Kappes JC: Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.

    Virology 1996, 219(1):307-313.


  18. Markowitz D, Goff S, Bank A: Construction of a safe and efficient retrovirus packaging cell line.

    Adv Exp Med Biol 1988, 241:35-40.


  19. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third-generation lentivirus vector with a conditional packaging system.

    J Virol 1998, 72(11):8463-8471.


  20. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ: Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

    J Virol 1998, 72(1):811-816.


  21. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.

    Nat Biotechnol 1997, 15(9):871-875.


  22. Chong H, Starkey W, Vile RG: A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences.

    J Virol 1998, 72(4):2663-2670.


  23. Garrett E, Miller AR, Goldman JM, Apperley JF, Melo JV: Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.

    Virology 2000, 266(1):170-179.


  24. Fletcher TM 3rd, Soares MA, McPhearson S, Hui H, Wiskerchen M, Muesing MA, Shaw GM, Leavitt AD, Boeke JD, Hahn BH: Complementation of integrase function in HIV-1 virions.

    Embo J 1997, 16(16):5123-5138.


  25. Wu X, Liu H, Xiao H, Conway JA, Hunter E, Kappes JC: Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.

    Embo J 1997, 16(16):5113-5122.


  26. Wu X, Liu H, Xiao H, Kim J, Seshaiah P, Natsoulis G, Boeke JD, Hahn BH, Kappes JC: Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.

    J Virol 1995, 69(6):3389-3398.


  27. Kobinger GP, Borsetti A, Nie Z, Mercier J, Daniel N, Gottlinger HG, Cohen A: Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

    J Virol 1998, 72(7):5441-5448.


  28. Yao XJ, Kobinger G, Dandache S, Rougeau N, Cohen E: HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect.

    Gene Ther 1999, 6(9):1590-1599.


  29. Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT, Kappes JC: Development of a novel trans-lentiviral vector that affords predictable safety.

    Mol Ther 2000, 2(1):47-55.


  30. Bryant M, Ratner L: Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

    Proc Natl Acad Sci U S A 1990, 87(2):523-527.


  31. Paillart JC, Gottlinger HG: Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting.

    J Virol 1999, 73(4):2604-2612.


  32. Spearman P, Horton R, Ratner L, Kuli-Zade I: Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism.

    J Virol 1997, 71(9):6582-6592.


  33. Spearman P, Wang JJ, Vander Heyden N, Ratner L: Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.

    J Virol 1994, 68(5):3232-3242.


  34. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor.

    J Biol Chem 1999, 274(13):9083-9091.


  35. Kondo E, Gottlinger HG: A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.

    J Virol 1996, 70(1):159-164.


  36. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L: A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

    J Virol 1995, 69(11):6873-6879.


  37. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR: Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.

    J Virol 1995, 69(12):7909-7916.


  38. Konvalinka J, Litterst MA, Welker R, Kottler H, Rippmann F, Heuser AM, Krausslich HG: An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

    J Virol 1995, 69(11):7180-7186.


  39. Strisovsky K, Tessmer U, Langner J, Konvalinka J, Krausslich HG: Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.

    Protein Sci 2000, 9(9):1631-1641.


  40. Imren S, Fabry ME, Westerman KA, Pawliuk R, Tang P, Rosten PM, Nagel RL, Leboulch P, Eaves CJ, Humphries RK: High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

    J Clin Invest 2004, 114(7):953-962.


  41. Iwakuma T, Cui Y, Chang LJ: Self-inactivating lentiviral vectors with U3 and U5 modifications.

    Virology 1999, 261(1):120-132.


  42. Malim MH, Hauber J, Fenrick R, Cullen BR: Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.

    Nature 1988, 335(6186):181-183.


  43. Maldarelli F, Martin MA, Strebel K: Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation.

    J Virol 1991, 65(11):5732-5743.


  44. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P: Correction of sickle cell disease in transgenic mouse models by gene therapy.

    Science 2001, 294(5550):2368-2371.


  45. Mizushima S, Nagata S: pEF-BOS, a powerful mammalian expression vector.

    Nucleic Acids Res 1990, 18(17):5322.


  46. Fuller M, Anson DS: Helper plasmids for production of HIV-1-derived vectors.

    Hum Gene Ther 2001, 12(17):2081-2093.


  47. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA: A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

    J Virol 2000, 74(10):4839-4852.


rating: 5.00 from 1 votes | updated on: 14 May 2008 | views: 11774 |

Rate article: